Endocyte Doses First Patient in Phase 1 SMDC EC1456 Trial in Advanced Solid Tumors

Endocyte (Nasdaq: ECYT ) today announced that it has dosed the first patient in its Phase 1 clinical trial in advanced solid tumors for its SMDC EC1456, a folate receptor (FR)-targeting folate-tubulysin conjugate. The open-label, multicenter, non-randomized, dose-escalation study is divided into two parts. The first part of the Phase